Forte Biosciences Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, has announced positive results from its Phase 1b trial for FB102 in the treatment of celiac disease. The study, which involved 32 subjects, demonstrated a significant improvement for those treated with FB102 compared to the placebo group. The trial reported a 73% improvement in the Vh:Cd ratio and a 42% reduction in gluten challenge-induced gastrointestinal symptoms for FB102-treated subjects. No dropouts or severe adverse events were reported. Forte Biosciences is set to initiate a Phase 2 celiac disease trial, with a topline readout expected in 2026. The results from the Phase 1b study were discussed in a conference call hosted by Forte Biosciences, featuring Prof. Jason Tye-Din, the principal investigator of the study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.